Log in | Register

Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study

Helge Røsjø| Ståle Nygård| Kirsi-Maija Kaukonen| Sari Karlsson| Mats Stridsberg| Esko Ruokonen| Ville Pettilä| Torbjørn Omland
Original
Volume 38, Issue 5 / May , 2012

Pages 820 - 829

Abstract

Purpose

To assess the prognostic information of chromogranin A (CgA), a marker associated with adrenergic tone and myocardial function, in patients with severe sepsis.

Methods

CgA levels were measured at the time of study inclusion and 72 h later in 232 patients with severe sepsis recruited from 24 ICUs in Finland (FINNSEPSIS study).

Results

Sixty-five patients (28 %) died during the index hospitalization. CgA levels at inclusion and after 72 h correlated with several established indices of risk in sepsis. Patients who died during the hospitalization had higher baseline CgA levels than hospital survivors: 14.0 (Q1–3, 7.4–27.4) versus 9.1 (5.9–15.8) nmol/l, P = 0.002, and after 72 h: 16.2 (9.0–31.1) versus 9.8 (6.0–18.0) nmol/l, P = 0.001. Prior cardiovascular disease (P = 0.04) and cardiovascular SOFA levels on day 3 (P = 0.03) were associated with higher CgA levels after 72 h by linear regression. CgA levels on study inclusion and after 72 h were independently associated with hospital mortality by logistic regression: OR (logarithmically transformed CgA levels) 1.95 (95 % CI 1.01–3.77), P = 0.046 and OR 2.03 (95 % CI 1.18–3.49), P = 0.01, respectively. The prognostic accuracy was comparable for CgA measurements and SAPS II score, and the addition of CgA measurements to the SAPS II score improved risk stratification of the patients as assessed by the category-free net reclassification index. A CgA level >6.6 nmol/l on study inclusion was associated with septic shock during the hospitalization.

Conclusion

CgA levels measured during hospitalization for severe sepsis are associated with cardiovascular dysfunction and may provide additional prognostic information in patients with severe sepsis.

Keywords

References

  1. Schuetz P, Christ-Crain M, Muller B (2007) Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 13:578–585
    • View reference on PubMed
    • View reference on publisher's website
  2. Røsjø H, Varpula M, Hagve TA, Karlsson S, Ruokonen E, Pettilä V, Omland T, FINNSEPSIS Study Group (2011) Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Med 37:77–85
  3. Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, Kolho E, Ruokonen E, Finnsepsis Study Group (2010) Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 14:R205
    • View reference on PubMed
    • View reference on publisher's website
  4. Groves AC, Griffiths J, Leung F, Meek RN (1973) Plasma catecholamines in patients with serious postoperative infection. Ann Surg 178:102–107
    • View reference on PubMed
    • View reference on publisher's website
  5. Fernandes Junior CJ, Iervolino M, Neves RA, Sampaio EL, Knobel E (1994) Interstitial myocarditis in sepsis. Am J Cardiol 74:958
    • View reference on PubMed
    • View reference on publisher's website
  6. Taupenot L, Harper KL, O’Connor DT (2003) The chromogranin-secretogranin family. N Engl J Med 348:1134–1149
    • View reference on PubMed
    • View reference on publisher's website
  7. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Parmer RJ, Barbosa JA, O’Connor DT (1990) Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 81:185–195
    • View reference on PubMed
    • View reference on publisher's website
  8. Cryer PE, Wortsman J, Shah SD, Nowak RM, Deftos LJ (1991) Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol 260:E243–E246
    • View reference on PubMed
  9. Dimsdale JE, O’Connor DT, Ziegler M, Mills P (1992) Chromogranin A correlates with norepinephrine release rate. Life Sci 51:519–525
    • View reference on PubMed
    • View reference on publisher's website
  10. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A (2007) Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 28:1117–1127
    • View reference on PubMed
    • View reference on publisher's website
  11. Røsjø H, Husberg C, Dahl MB, Stridsberg M, Sjaastad I, Finsen AV, Carlson CR, Øie E, Omland T, Christensen G (2010) Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium. Circ Heart Fail 3:503–511
    • View reference on PubMed
    • View reference on publisher's website
  12. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR (2011) The extended granin family: structure, function, and biomedical implications. Endocr Rev 32:755–797
  13. Mazza R, Imbrogno S, Tota B (2010) The interplay between chromogranin A-derived peptides and cardiac natriuretic peptides in cardioprotection against catecholamine-evoked stress. Regul Pept 165:86–94
    • View reference on PubMed
    • View reference on publisher's website
  14. Omland T, Dickstein K, Syversen U (2003) Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med 114:25–30
    • View reference on PubMed
    • View reference on publisher's website
  15. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K, Omland T (2006) Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 152(927):e1–e6
    • View reference on PubMed
  16. Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, Caidahl K (2009) Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 30:25–32
    • View reference on PubMed
    • View reference on publisher's website
  17. Dieplinger B, Gegenhuber A, Struck J, Poelz W, Langsteger W, Haltmayer M, Mueller T (2009) Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta 400:91–96
    • View reference on PubMed
    • View reference on publisher's website
  18. Karlsson S, Varpula M, Ruokonen E, Pettilä V, Parviainen I, Ala-Kokko TI, Kolho E, Rintala EM (2007) Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 33:435–443
  19. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
  20. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
  21. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V (2007) Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 35:1277–1283
    • View reference on PubMed
    • View reference on publisher's website
  22. Stridsberg M, Eriksson B, Öberg K, Janson ET (2003) A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 177:337–341
    • View reference on PubMed
    • View reference on publisher's website
  23. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
    • View reference on PubMed
    • View reference on publisher's website
  24. Nguyen HB, Kuan WS, Batech M, Shrikhande P, Mahadevan M, Li CH, Ray S, Dengel A, The ATLAS (Asia Network to Regulate Sepsis care) Investigators (2011) Outcome effectiveness of the severe sepsis resuscitation bundle with addition of lactate clearance as a bundle item: a multi-national evaluation. Crit Care 15:R229
    • View reference on PubMed
    • View reference on publisher's website
  25. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845
    • View reference on PubMed
    • View reference on publisher's website
  26. Pencina MJ, D’Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11–21
    • View reference on PubMed
    • View reference on publisher's website
  27. Zhang D, Lavaux T, Voegeli AC, Lavigne T, Castelain V, Meyer N, Sapin R, Aunis D, Metz-Boutigue MH, Schneider F (2008) Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 54:1497–1503
    • View reference on PubMed
    • View reference on publisher's website
  28. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T (2010) Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 43:714–719
    • View reference on PubMed
    • View reference on publisher's website
  29. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T (2009) Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95:1508–1513
    • View reference on PubMed
    • View reference on publisher's website
  30. Leinhardt DJ, Arnold J, Shipley KA, Mughal MM, Little RA, Irving MH (1993) Plasma NE concentrations do not accurately reflect sympathetic nervous system activity in human sepsis. Am J Physiol 265:E284–E288
    • View reference on PubMed
  31. Dimsdale JE, Ziegler MG (1991) What do plasma and urinary measures of catecholamines tell us about human response to stressors? Circulation 83:II36-II42
  32. O’Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ (1989) Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 35:1631–1637
    • View reference on PubMed
  33. Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, LaRovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, GISSI-HF Investigators (2010) Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail 12:549–556
    • View reference on PubMed
    • View reference on publisher's website
  34. Portela-Gomes GM, Stridsberg M (2002) Chromogranin A in the human gastrointestinal tract: an immunocytochemical study with region-specific antibodies. J Histochem Cytochem 50:1487–1492
    • View reference on PubMed
    • View reference on publisher's website
  35. Lugardon K, Raffner R, Goumon Y, Corti A, Delmas A, Bulet P, Aunis D, Metz-Boutigue MH (2000) Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 275:10745–10753
    • View reference on PubMed
    • View reference on publisher's website
  36. Bendel S, Karlsson S, Pettilä V, Loisa P, Varpula M, Ruokonen E (2008) Free cortisol in sepsis and septic shock. Anesth Analg 106:1813–1819
    • View reference on PubMed
    • View reference on publisher's website
  37. Karlsson S, Pettilä V, Tenhunen J, Lund V, Hovilehto S, Ruokonen E (2008) Vascular endothelial growth factor in severe sepsis and septic shock. Anesth Analg 106:1820–1826
    • View reference on PubMed
    • View reference on publisher's website
  38. Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E (2008) HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 34:1046–1053
  39. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15:R63
    • View reference on PubMed
    • View reference on publisher's website
  40. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, Rao F, Stridsberg M, Ziegler MG, Mahata SK, O’Connor DT (2010) Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 32:278–287
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement